{"schema_version":"1.0","type":"article","title":"兩款口服大環肽新藥獲批：大藥廠押注的，不只是一顆藥片","url":"https://drugnews.com.tw/articles/2026-09-06-oral-macrocyclic-peptide-platform.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-06-oral-macrocyclic-peptide-platform.md","lang":"zh-Hant","date":"2026-09-06","publish_at":"2026-09-06T08:00:00+08:00","updated_at":"2026-09-06","category":"商業分析系列","topic":"商業分析系列","tags":["口服大環肽","oral macrocyclic peptide","藥物開發","口服生物可用率"],"summary":"ICOTYDE 與 LIPFENDRA 為口服大環肽帶來兩項核准里程碑，但 LDL-C 改善不等於心血管結局已證實；平台價值仍要跨過人體暴露、治療窗、製造與可複製性考驗。","key_points":[],"facts":[],"sections":["一、第一站：替注射藥開一扇口服門","二、兩張藥證落地前，大藥廠早已先用交易卡位","三、真正的分水嶺，不在腸道，而在細胞膜","四、從能吃到能賺，還要過四道關","五、投資人真正該算的，是平台能否複製"],"references":[],"images":[{"alt":"小分子、閉環肽與未結合抗原的抗體之概念比較；抗體兩臂標示 Fab，下方柄部為 Fc。","url":"https://drugnews.com.tw/assets/articles/oral-macrocyclic-peptide-platform/01_molecular_format_zh_r2.png"},{"alt":"ICOTYDE 在細胞外側結合跨膜 IL-23 受體；LIPFENDRA 結合游離 PCSK9，阻斷其與肝細胞 LDL 受體交互作用。","url":"https://drugnews.com.tw/assets/articles/oral-macrocyclic-peptide-platform/02_extracellular_targets_zh_r4.png"},{"alt":"已核准產品、平台合作與第一期研究分成三個獨立區塊；前期付款與有條件里程碑分開，AUBE00 與 CID-078 尚屬研究中。","url":"https://drugnews.com.tw/assets/articles/oral-macrocyclic-peptide-platform/03_evidence_maturity_zh_r3.png"},{"alt":"口服大環肽開發的四項評估：人體暴露、患者使用體驗、治療窗，以及製程放大與品質。","url":"https://drugnews.com.tw/assets/articles/oral-macrocyclic-peptide-platform/04_development_gates_zh_r2.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/oral-macrocyclic-peptide-platform/00_cover_no_text_r1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-06）。兩款口服大環肽新藥獲批：大藥廠押注的，不只是一顆藥片。https://drugnews.com.tw/articles/2026-09-06-oral-macrocyclic-peptide-platform.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}